| Features: |
| Osimertinib works by selectively inhibiting the activity of EGFR, which is a protein that plays a critical role in the growth and survival of cancer cells. By blocking the activity of EGFR, osimertinib prevents the growth and proliferation of cancer cells, leading to tumor shrinkage and improved survival. Osimertinib has been shown to be effective in patients with NSCLC who have specific EGFR mutations. In the AURA3 trial, osimertinib significantly improved progression-free survival (PFS) compared with platinum-based chemotherapy. In the FLAURA trial, osimertinib significantly improved PFS and overall survival (OS) compared with erlotinib or gefitinib. |
| Source: |
| Type: type of cell death |
| Type of programmed cell death dependent on iron. Ferroptosis is a form of regulated cell death characterized by the accumulation of lipid peroxides to lethal levels. It is distinct from other forms of cell death, such as apoptosis, necrosis, and autophagy. The process of ferroptosis is heavily dependent on iron metabolism and reactive oxygen species (ROS). The accumulation of lipid peroxides is a hallmark of ferroptosis. This can occur when the antioxidant defenses, such as glutathione and selenoproteins, are overwhelmed or inhibited. Many cancer cells upregulate GPX4 to evade ferroptosis, making it a potential target for therapy. It has been described that GPX4, xCT and ACSL-4 are the main targets in the regulation of ferroptosis. |
| 1002- | SSE, | Osi, | Adag, | Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H385 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:253 Target#:114 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid